<?xml version='1.0' encoding='utf-8'?>
<document id="31773427"><sentence text="Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects."><entity charOffset="79-88" id="DDI-PubMed.31773427.s1.e0" text="Midazolam" /></sentence><sentence text="Aprocitentan is an orally active dual endothelin receptor antagonist that targets a novel pathway in the treatment of difficult-to-control (resistant) hypertension" /><sentence text=" The drug-drug interaction potential of aprocitentan on cytochrome P450 (CYP) 3A enzymes was investigated in this open-label, two-treatment single-sequence study" /><sentence text="" /><sentence text="The primary and main secondary objectives were to study the pharmacokinetics of midazolam in the absence and presence of aprocitentan and the safety and tolerability of combined administration, respectively"><entity charOffset="80-89" id="DDI-PubMed.31773427.s5.e0" text="midazolam" /><entity charOffset="121-133" id="DDI-PubMed.31773427.s5.e1" text="aprocitentan" /><pair ddi="false" e1="DDI-PubMed.31773427.s5.e0" e2="DDI-PubMed.31773427.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31773427.s5.e0" e2="DDI-PubMed.31773427.s5.e1" /></sentence><sentence text="" /><sentence text="Nineteen healthy male subjects received a single dose of 8 mg midazolam" /><sentence text=" Thereafter, they started aprocitentan treatment (loading dose of 150 mg followed by 50 mg once daily) and received another single dose of midazolam with aprocitentan at steady state"><entity charOffset="139-148" id="DDI-PubMed.31773427.s8.e0" text="midazolam" /><entity charOffset="154-166" id="DDI-PubMed.31773427.s8.e1" text="aprocitentan" /><pair ddi="false" e1="DDI-PubMed.31773427.s8.e0" e2="DDI-PubMed.31773427.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31773427.s8.e0" e2="DDI-PubMed.31773427.s8.e1" /></sentence><sentence text=" Pharmacokinetics and tolerability of midazolam and its metabolite 1-hydroxy midazolam were assessed over 24 h after each midazolam administration"><entity charOffset="38-47" id="DDI-PubMed.31773427.s9.e0" text="midazolam" /><entity charOffset="67-86" id="DDI-PubMed.31773427.s9.e1" text="1-hydroxy midazolam" /><pair ddi="false" e1="DDI-PubMed.31773427.s9.e0" e2="DDI-PubMed.31773427.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31773427.s9.e0" e2="DDI-PubMed.31773427.s9.e1" /></sentence><sentence text="" /><sentence text="At steady state, aprocitentan did not affect the area under the plasma concentration-time curve and maximum plasma concentration (Cmax) of midazolam and 1-hydroxy midazolam, with a geometric means ratio (GMR) of midazolam + aprocitentan/midazolam alone close to 1 and 90% confidence intervals (CI) between 0"><entity charOffset="139-148" id="DDI-PubMed.31773427.s11.e0" text="midazolam" /><entity charOffset="153-172" id="DDI-PubMed.31773427.s11.e1" text="1-hydroxy midazolam" /><entity charOffset="212-236" id="DDI-PubMed.31773427.s11.e2" text="midazolam + aprocitentan" /><entity charOffset="237-246" id="DDI-PubMed.31773427.s11.e3" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.31773427.s11.e0" e2="DDI-PubMed.31773427.s11.e0" /><pair ddi="false" e1="DDI-PubMed.31773427.s11.e0" e2="DDI-PubMed.31773427.s11.e1" /><pair ddi="false" e1="DDI-PubMed.31773427.s11.e0" e2="DDI-PubMed.31773427.s11.e2" /><pair ddi="false" e1="DDI-PubMed.31773427.s11.e0" e2="DDI-PubMed.31773427.s11.e3" /><pair ddi="false" e1="DDI-PubMed.31773427.s11.e1" e2="DDI-PubMed.31773427.s11.e1" /><pair ddi="false" e1="DDI-PubMed.31773427.s11.e1" e2="DDI-PubMed.31773427.s11.e2" /><pair ddi="false" e1="DDI-PubMed.31773427.s11.e1" e2="DDI-PubMed.31773427.s11.e3" /><pair ddi="false" e1="DDI-PubMed.31773427.s11.e2" e2="DDI-PubMed.31773427.s11.e2" /><pair ddi="false" e1="DDI-PubMed.31773427.s11.e2" e2="DDI-PubMed.31773427.s11.e3" /></sentence><sentence text="88 and 1" /><sentence text="23" /><sentence text=" For the Cmax of 1-hydroxy midazolam the GMR (90% CI) was 0"><entity charOffset="17-36" id="DDI-PubMed.31773427.s14.e0" text="1-hydroxy midazolam" /></sentence><sentence text="86 (0" /><sentence text="70-1" /><sentence text="05)" /><sentence text=" Somnolence, a known side-effect of midazolam, was reported as the most frequent adverse event"><entity charOffset="36-45" id="DDI-PubMed.31773427.s18.e0" text="midazolam" /></sentence><sentence text=" There were no relevant differences in tolerability parameters between treatments" /><sentence text="" /><sentence text="Aprocitentan does not alter the pharmacokinetics of midazolam to a clinically relevant extent and was well tolerated when administered concomitantly"><entity charOffset="52-61" id="DDI-PubMed.31773427.s21.e0" text="midazolam" /></sentence><sentence text=" Therefore, aprocitentan can be administered together with drugs that are substrates of CYP3A without dose adjustments"><entity charOffset="12-24" id="DDI-PubMed.31773427.s22.e0" text="aprocitentan" /></sentence><sentence text="" /></document>